Sunvozertinib

Overview

Sunvozertinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL5314564).

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Sunvozertinib expires 28 Jan 2039 and exclusivity 2 Jul 2030. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide

Canonical SMILES

CC(C)(C1=CC(=C(C=C1NC2=NC(=NC=C2)NC3=C(C=C(C(=C3)NC(=O)C=C)N4CC[C@H](C4)N(C)C)OC)Cl)F)O

InChIKey

BTMKEDDEMKKSEF-QGZVFWFLSA-N